To determine which risk factors are relevant to the occurrence of post-herpetic neuralgia in Japanese patients with acute herpes zoster, correlations between the prolongation of pain and various disease factors were examined in 263 adult patients presenting within 10 days of the onset of rash at 17 institutions in the Hyogo region of Japan. All patients in whom pain persisted for more than 3 months were over 60 years of age. The pain also tended to be more prolonged in those with clustered vesicles, disturbed sleep and hypaesthesia. Other factors such as underlying disease states, critically involved regions, scar tissue, generalized rash and allodynia were not relevant to the duration of pain. Although decreased pain persistence was observed in patients in whom acyclovir therapy was initiated within 72 h of the onset of symptoms in comparison with those in whom it was initiated after this time, the difference between the two groups of patients was not statistically significant. Our results suggest that advanced age, the presence of clustered vesicles, and disturbed sleep and hypaesthesia influence the prolongation of herpes zoster pain.
Introduction
Herpes zoster is commonly encountered in daily medical practice in Japan. Symptoms vary individually depending on factors such as age, affected site, severity of the eruptions, underlying disease states and immune status. In managing herpes zoster, it is important to diagnose accurately and understand the pathogenesis of the condition, and to institute early appropriate treatment. Dermatologists have traditionally tended to focus on the skin eruptions while anaesthetists have focused on pain. We therefore formed a study group that involved both dermatologists and anaesthetists (the Hyogo Prefectural PHN Study Group) to investigate the occurrence of post-herpetic neuralgia (PHN) in herpes zoster patients, and undertook co-ordinated clinical surveillance at 17 institutions in the Hyogo region ( Table 1) .
Post-herpetic neuralgia is one of the most troublesome complications of herpes zoster in immunocompetent patients 1 and is estimated to occur in 10% of cases, 1,2 but its pathogenesis remains unclear. 2 At present, no effective therapy for PHN has been established, 3 but pain control in the acute phase of herpes zoster is considered the most I Kurokawa, K Kumano, K Murakawa et al. Clinical correlates of post-herpetic neuralgia effective strategy for its prophylaxis. In this regard, early treatment with acyclovir has been found useful for PHN prophylaxis, 4 although it has also been reported to have no effect on the incidence and severity of PHN. 5 The risk factors that have been proposed for PHN include advanced age, 1, 6, 7 severe pain in the early phase of the infection, intercurrence of paraesthesia and motor paralysis and infection in the area of the trigeminal nerve, 1 -3,8 extensive and severe eruptions, 9 and underlying diseases such as diabetes, 10 collagenosis and malignant tumours.
The aim of our co-ordinated clinical surveillance programme was to determine which of these risk factors is relevant to the occurrence of PHN in Japanese patients, and to apply this knowledge in formulating a strategy for PHN prophylaxis.
Patients and methods PATIENTS
A total of 263 patients (127 males; 136 females) with herpes zoster in the acute phase presenting within 10 days of the onset of rash were studied. Patients with renal dysfunction were excluded.
SURVEILLANCE PROCEDURE
A clinical assessment was performed at the patients' first clinic visit (day 1), and then at 3 or 4 days, 1, 2 and 3 weeks and 1, 2, 3, 4 and 6 months after the initial visit. The following were recorded on case report forms, summarized and subjected to statistical analysis: (i) Patient demographic factors: age, sex, underlying diseases and concomitant diseases; (ii) Affected site: the critically affected region and innervation; (iii) Prodromal factors: onset time and observed symptoms; (iv) Eruption: presence or absence of erythema, erosion, ulcer, scar and generalized rash. Vesicles, pustules and crusts were evaluated and graded as either none, mild or severe. Whether a large number of vesicles were clustered together was also recorded; (v) Pain: the severity of pain was subjectively evaluated by patients using the visual analogue scale (VAS); (vi) Quality of pain: the patients' pain was classified into five different types as: 'stabbing', 'tightening', 'throbbing', 'burning' or 'pricking'. Its severity was graded as either none (score: 0), mild (score: 1) or severe (score: 2). Whether insomnia, hypaesthesia and allodynia (pain in normal skin) were present was also recorded; (vii)Drug administration: the dose of acyclovir administered (all patients received either oral or intravenous acyclovir therapy) and whether concomitant medication, including nerve blocks, were given.
FOLLOW-UP EXAMINATION
A questionnaire (facilitated by a return postcard) was conducted to provide information on the patients' pain status over the 6-month study period. The questionnaires were sent to all 263 patients to provide data on the persistence and severity of the pain as assessed by the VAS technique. Pain severity was rated as either 'very severe', 'severe' or 'mild'.
STATISTICAL ANALYSIS
The data obtained were analysed by an unpaired t-test.
Results

PATIENTS
A total of 263 patients (127 males, 136 females) were studied. The mean age of the patients was 59 years (range, 20 -95 years). Their age and sex distribution is shown in Fig. 1 . Peak incidences were in patients of both sexes aged 60 -69 years, and in women aged 50 -59 years. The critically affected region most frequently observed was the area served by the thoracic spinal nerves (50.9%), followed by the areas served by the trigeminal nerve (21.8%), cervical nerves (13.4%), lumbar nerves (9.7%) and sacral nerves (4.2%) ( Fig. 2 ). Using a dermatomal segment classification, the region most commonly involved was that served by the first branch of the trigeminal nerve (21 patients), followed by the area innervated by the twelfth branch of the thoracic nerve (Th 12) (13 patients).
The principal underlying diseases identified were: malignant tumours in 36 patients (13.7%), diabetes in 26 (9.9%) and hepatic disease in 13 (4.9%); however, 58.9% of patients did not have any underlying disease (Fig. 3 ).
The prodrome most frequently reported was pain, which was noted by 88.5% of patients. Among concomitant medications taken, oral non-steroidal, anti-inflammatory drugs (NSAIDs), oral vitamin preparations, and topical NSAID formulations were used by 58%, 39.2% and 32.1% of patients, respectively (inclusive of combination use). Over the study period, a decrease in the mean visual analogue scale (VAS) pain score with time was observed in patients with all five critically involved regions ( Fig. 4A ). Undue prolongation of pain in the area served by the trigeminal nerve was not observed, and there was no difference in the persistence of pain between males and females. When patient age, which is one of the principal risk factors for PHN, was examined, it was observed that all of the patients in whom pain persisted for 3 months or longer were aged ≥ 60 years ( Fig. 4B , P < 0.01). Mean VAS pain scores in patients who had eruptions of densely clustered vesicles were significantly higher at 1 month than in patients with scattered vesicles ( sleep or hypaesthesia; the mean change in VAS pain scores from baseline to 1 month differed significantly between those with versus those without disturbed sleep or hypaesthesia ( Fig. 4D , P < 0.01; Fig. 4E , P < 0.01).
When the nature of pain was examined, scores for 'throbbing' or 'pricking' pain decreased significantly with time, but scores in patients who complained of 'stabbing', 'tightening' or 'burning' pain decreased little with time ( Fig. 5 ).
Other risk factors examined, including the presence or absence of critically affected regions, underlying diseases, immunodeficiency, erosion, ulcer, scar, generalized rash, allodynia, grade of erythema and crusting, and nerve blocks or other concomitant medications did not show any statistically significant correlation with the prolongation of pain. In addition, changes in VAS pain scores were not different between intravenous infusion and oral administration of acyclovir, and there was no difference between patients who started acyclovir therapy within 72 h of the onset of symptoms and those who started it after this time.
FOLLOW-UP ASSESSMENT
Answers to the follow-up questionnaire were available for 141 patients (65 males; 76 females), i.e. approximately half of the total number of patients studied. Persistence of pain at 6 months after the initial visit was reported by 37 patients (26.2%). The mean VAS score in these patients was 2.9, and the pain was rated as 'severe' in 21.4% and 'mild' in 73%. Most (94.5%) of the 141 respondents were 50 years of age or more.
Although persistence of PHN was observed more frequently in females than in males (24 versus 13, respectively), the difference was not statistically significant. Pain persistence was highest in patients who exhibited symptoms in areas served by the trigeminal nerve (Fig. 6) .
In relation to acyclovir therapy, the pain persistence rate was 17.9% in patients in whom acyclovir therapy was started within 72 h of the onset of symptoms and 28.7% in those in whom it was started after this time, but the difference between the two groups was not statistically significant. Moreover, the pain persistence rate was no different between those who received intravenous infusions of acyclovir and those who received oral therapy. 
Discussion
Herpes zoster is a disease produced by the reactivation and afferent movement along sensory nerves of varicella zoster virus that has incubated in trigeminal nerve and spinal dorsal root ganglia following an earlier episode of chickenpox. The initial clinical symptoms are oedematous erythema with unilateral pain, followed by the appearance of vesicles and blisters and the formation of pustules, resulting in dryness and crusting. In those with severe dermatological symptoms, a generalized rash is observed and ulcers and scars may occur. Until relatively recently there was no effective therapy for acute herpes zoster, but with the introduction of effective antiviral agents, management of the condition has altered completely. However, PHN still occurs in many patients as a result of insufficient treatment in the early phase of the disease. Therefore, it is important to evaluate objectively the clinical outcome in patients with acute herpes zoster according to factors such as age, critically involved regions, severity, general condition and underlying disease states in order to be able to provide appropriate treatment for each individual patient.
The most troublesome complication of herpes zoster in immunocompetent patients is PHN, which occurs in approximately 10% of cases. The International Association for the Study of Pain has defined PHN as 'chronic pain accompanied by dermatic change in dermatomal segments after acute herpes zoster'. However, the duration of PHN is not included in this definition. Although some authorities consider the duration of pain to be 1 month, 7 others believe that it is 2 -3 months. It has been demonstrated that the risk of PHN increases with ageing. In the present study, pain disappeared within 2 months in patients under 60 years of age, but persisted for more than 3 months in patients over 60 years of age. Thus, our findings suggest that 2 -3 months may be more appropriate as the standard duration of PHN.
In terms of critically involved regions, there are numerous reports 1, 2, 11 indicating that herpes zoster ophthalmicus is highly correlated with PHN, although one study 8 has suggested no such correlation. In the patients we studied, there was no correlation between critically involved regions and the occurrence of PHN.
In terms of gender differences, PHN has been reported to occur in females more frequently than in males, 7 and our data from the follow-up questionnaire indicated that the female:male occurrence ratio was about 2:1. However, this difference was not statistically significant.
Although the pathogenesis of PHN is not well known, inflammation of sensory nerve ganglia, destruction of nerve cells, fibrillation of sensory nerves and a decrease in and fibrillation of peripheral nerve fibres at critically involved sites have been demonstrated. Noordenbos et al. 12 reported a decrease in myelinated nerve fibre and an increase in unmyelinated fibre. Although objective evaluation of pain is difficult, the VAS technique is commonly used. Whereas 'stabbing', 'tightening' and 'burning' pain were prolonged in our patients and the VAS scores for these types of pain changed little with time, VAS scores for 'throbbing' and 'pricking' pain did decrease with time. These results may indicate that the former pain types are strongly associated with nerve degeneration, whereas the latter are associated more with inflammatory factors.
In terms of the severity of the eruption, Higa et al. 9, 13 have demonstrated a correlation between this factor and pain prolongation when using a dermatomal segment classification. However, there have been no reports of a correlation between the characteristics of the eruption and PHN. In the present study, prolongation of pain was evident in patients with densely clustered vesicles in comparison with those with scattered vesicles. Although we had predicted persistence of PHN in patients with ulcer and scar formation and those with a generalized rash, there was no statistically significant correlation between these factors and the persistence of PHN.
Disturbed sleep and hypaesthesia are recognized as relevant to PHN. Disturbed sleep has been reported to relate to pain in the acute phase of herpes zoster 14 (although a correlation between PHN and disturbed sleep has not previously been reported), and there has been one report 11 suggesting a correlation of hypaesthesia in critically affected regions to PHN. Allodynia did not show a statistically significant correlation to PHN in our study and nor did underlying diseases such as malignant tumours, diabetes and hepatic diseases; however, complications of diabetes have been reported to cause PHN. 10 The risk of PHN in those patients in our study who had immunodeficiencies was no higher than in patients who are immunocompromised. 15, 16 The number of the patients who did not return for their clinic visits increased with time; therefore, only 141 follow-up questionnaires were available for analysis and follow-up data were available for only about half of the original 263 patients studied. Persistence of pain was reported by 37 patients, which, if 'no reply' cases are included in the analysis, equates to 14.1% of the total number of patients. This rate is slightly higher than that described in previous reports. 1 Oral or intravenous administration of acyclovir is a standard therapeutic measure in the management of acute herpes zoster. The present study was not designed to compare acyclovir with placebo as acyclovir was administered to all patients. Since it has been demonstrated that acyclovir significantly decreases the pain of acute herpes zoster and reduces the duration of the eruption compared with placebo, 17,18 it would not have been ethically possible to include a placebo arm in the trial. Thus, we did not investigate whether acyclovir is effective in the prophylaxis of PHN. In this regard, Wood et al. 5 found that acyclovir therapy did not influence the incidence and severity of PHN, contrary to the finding
